Política de cookies

Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso.

Más información
Permissions Requests - Help - - Sign up - Phone number 902 888 740

2016 FI

© Thomson Reuters, Journal Citation Reports, 2016

Indexed in:

Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME Cancerlit, Bibliomed, CabHealth, Scisearch, HealthStar, Scopus, Prous, Science Intergews, Science Citation Index Expanded.


  • Impact Factor: 1.439 (2016)
  • CiteScore 2017: 1.24
    Read more
  • SCImago Journal Rank (SJR):0,504
  • Source Normalized Impact per Paper (SNIP):0,791

© Thomson Reuters, Journal Citation Reports, 2017

Allergol Immunopathol (Madr) 2018;46:149-54 - DOI: 10.1016/j.aller.2017.06.005
Original Article
Cross-over clinical trial for evaluating the safety of camel's milk intake in patients who are allergic to cow's milk protein
E.M. Navarrete-Rodrígueza, L.A. Ríos-Villalobosa, C.R. Alcocer-Arreguína, B.E. Del-Rio-Navarroa,, , J.M. Del Rio-Chivardia, O.J. Saucedo-Ramíreza, J.J.L. Sienra-Mongeb, R.V. Friasc
a Department of Allergy and Clinical Immunology, Hospital Infantil de México Federico Go¿mez, Ciudad de México, Mexico
b Department of Ambulatory Pediatrics, Hospital Infantil de México Federico Go¿mez, Ciudad de México, Mexico
c Department of Gastroenterology and Nutrition, Hospital Infantil de México Federico Go¿mez, Ciudad de México, Mexico
Received 24 March 2017, Accepted 21 June 2017

Cow's milk protein allergy (CMPA) affects between 0.6 and 0.9% of the general population, and its treatment implies the total elimination of the intake of this protein. Camel's milk has been suggested as an alternative for patients over one year of age who suffer from CMPA due to the difference in the amino acid sequence from that of cow's milk. The objective of this study was to evaluate the safety and tolerability of camel's milk in children with CMPA.


Crossed clinical trial for the use of camel's milk vs. amino acid formula, carried out at the Dr. Federico Gómez Children's Hospital of Mexico (HIMFG) on patients between one and 18 years of age with diagnosed CMPA confirmed through double-blind, placebo-controlled food challenges (DBPCFCs). Only those whose allergies were confirmed were randomly placed into two groups: those to be administered camel's milk and those to be administered the amino-acid formula for two weeks, followed by a six-week wash-out period, and then a group crossing for a further two weeks.


49 patients with suspected CMPA were included in the study; the diagnosis was confirmed through DBPCFCs in 15 patients, who were those who participated in the study. After having been administered camel's milk, none of the patients presented adverse effects.

Conclusions and clinical relevance

Camel's milk is safe and tolerable in patients above one year of age with CMPA and can be considered as a good alternative given the benefit of its taste compared to other formulas.

Download PDF


Read the complete contents of this article

Already registered?